Multi-Target Directed Drug for Alzheimer’s
Alzheimer’s disease (AD) is estimated to afflict 4 million people in the US. The current treatments are limited to symptomatic treatment of cognitive function. The main challenge in AD treatment is its apparent multi- factorial nature. This necessitates the progression from single-target drug development to multi-target.
The invention is a series of novel compounds that are useful for the treatment and prevention of Alzheimer’s disease. These compounds target multiple risk factors involved in AD including amyloid-β oligomers (AβO) oxidative stress and biometals and cell membrane/lipid rafts. The multifunctional Aβ oligomerization inhibitors (BMAOIs) strategy targeting CM/LR and other factors involved in the etiology of AD might be an ideal approach to overcome the limits of traditional single-target based approach.
Please see journal article- Lenhart et al. J. Med. Chem. 2010, 53, 6198–6209.
- Multi-targeted approach to treat Alzheimer’s disease
- Studies indicate ligand crosses blood-brain-barrier
- Treatment of Alzheimer’s disease
- Inhibit amyloid-β oligomers, oxidative stress, biometals and lipid rafts
- Potential to slow the progression of Alzheimer’s disease
- Diagnostic Imaging of beta-amyloid plaques
Shijun Zhang, Ph.D.
Patent pending: U.S. rights are available - 13/810,826
This technology is available for licensing to industry for further development and commercialization.
VCU Tech #:
Contact us about
Magdalena K. Morgan, Ph.D.